michael west

Professor of Medicine

Dalhousie University

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael West is a Professor of Medicine at Dalhousie University in Canada. His research focuses on Fabry disease and includes recent publications on gene therapy, nephropathy, and long-term follow-ups of treatment efficacy. Additionally, he investigates the cost-effectiveness of independent registries for orphan medicinal products and standardizes clinical outcome measures for adult clinical trials in Fabry disease.

Articles (11)

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

C. E. M. Hollak

NETHERLANDS

View details

Dwayne Barber

University Health Network

CANADA

View details

Juan Torras

Professor

University of Barcelona

SPAIN

View details

Mirjam Langeveld

NETHERLANDS

View details

Armand Keating

Professor

University of Toronto

CANADA

View details

Christiane Auray-Blais

Full professor

Université de Sherbrooke

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

michael west

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Fabry nephropathy: a treatable cause of chronic kidney disease

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease

Lentivirus-mediated gene therapy for Fabry disease.

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process

Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing

Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus

Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: Findings from the opinion-based PREDICT-FD modified Delphi consensus initiative

Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report

Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres

Collaborators (6)

C. E. M. Hollak

Dwayne Barber

Juan Torras

Mirjam Langeveld

Armand Keating

Christiane Auray-Blais

Make your next move.